Telavancin

Drug Profile

Telavancin

Alternative Names: Arbelic; TD-6424; Telavancin hydrochloride; Vibativ

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Theravance
  • Developer Clinigen; Innoviva; PENDOPHARM; Theravance Biopharma; University of Illinois at Chicago
  • Class Aminoglycosides; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell membrane permeability enhancers; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Skin and soft tissue infections

Highest Development Phases

  • Marketed Nosocomial pneumonia; Skin and soft tissue infections
  • Registered Bacteraemia
  • Phase III Osteomyelitis
  • Phase I Bacterial infections
  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 05 Jun 2017 Antimicrobial data from preclinical studies in Bacterial infections presented at the annual meeting of the American Society for Microbiology (ASM-2017)
  • 20 Apr 2017 Telavancin is available for licensing in (excluding USA) as of 19 Apr 2017. www.theravance.com
  • 27 Feb 2017 Theravance announces intention to submit sNDA to US FDA for bacteraemia in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top